Press Releases

NORTH CHICAGO, Ill., Nov. 8, 2019 /PRNewswire/ -- In accordance with Rule 2.10 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013, AbbVie Inc. confirms that as of November 6, 2019 its issued share capital, excluding treasury shares, is comprised of 1,478,830,254 shares of common stock with a par value of $

LUND, Sweden, Nov. 8, 2019 /PRNewswire/ -- BioInvent International AB (publ) (OMXS: BINV) today announces it will make a poster presentation with preclinical data on BI-1206 at the annual American Society of Hematology (ASH) meeting in Orlando, Florida held December 7-10. The abstract, published

CAMBRIDGE, England and BOSTON, Nov. 8, 2019 /PRNewswire/ -- Abcam plc, a global innovator in life science reagents and tools, is today pleased to announce a strategic partnership with BrickBio, experts in site-specific protein modification and a Tiger Gene portfolio company, covering the use of BrickBio's proprietary platform for introducing conjugation-ready sites

WINDSOR LOCKS, Conn., Nov. 8, 2019 /PRNewswire/ -- Internet conference information is at:  http://ritualabuse.us/smart-conference/ Complimentary l

LUND, Sweden, Nov. 8, 2019 /PRNewswire/ -- Camurus AB (NASDAQ STO: CAMX) today announces that the U.S. Food and Drug Administration (FDA) has granted Camurus' US partner Braeburn's request (through Citizen Petition) to revoke orphan drug designation of Sublocade™.1In a separate decision FDA upheld its previous tentative approval decision, with the

PLYMOUTH MEETING, Pa., Nov. 7, 2019 /PRNewswire/ -- Braeburn Inc. is pleased to confirm that it will seek, and is eligible for, marketing approval for BRIXADI™ (buprenorphine) weekly and monthly extended-release injection for the treatment of OUD as of December 1, 2020. This follows from today's decision by the U.S. Food and Drug Admin

NORTH CHICAGO, Ill., Nov. 7, 2019 /PRNewswire/ -- AbbVie Inc. (NYSE:ABBV) ("AbbVie") announced today that the requisite number of consents have been received to adopt certain proposed amendments (the "Amendments") with respect to all outstanding notes of certain series issued by Allergan Finance, LLC ("Allergan Finance"), Allergan, Inc. ("Allergan Inc"), Allergan Sales,

HOUSTON, Nov. 7, 2019 /PRNewswire/ -- CNS Pharmaceuticals, Inc. ("Company"), a pre-clinical stage biotechnology company specializing in the development of novel treatments for brain tumors, today announced the pricing of its initial public offering of 2,125,000 shares of common stock at an offering price of $4.00 per share. The gross pr

In the news release, Apollo Medical Holdings, Inc. Reports: 3Q19 Total Revenues of $156.1 Million, Up 20.0% Over 2Q19; 3Q19 Adjusted EBITDA of $22.8 Million, Up 55.6% Over 3Q18; Capitated Membership of Over One Million Managed Lives; and Elite Status Awarded by APG, issued 07-Nov-2019 by Apollo Medical Holdings, Inc. over PR Newswire, we are ad

NEW YORK, Nov. 7, 2019 /PRNewswire/ -- Welltower Inc. (NYSE: WELL) today was honored at the Women's Forum of New York 2019 Breakfast of Corporate Champions for achieving 40% representation of women on its Board of Directors. Since the announcement of the awards earlier this fall, the percentage of female Independent Directors on the